# Envofolimab and Lenvatinib Combined With Gemcitabine Plus Cisplatin for Advanced BTC as First-Line Treatment(ENLIGHTEN)

> **NCT05410197** · PHASE2 · UNKNOWN · sponsor: **Sun Yat-sen University** · enrollment: 43 (estimated)

## Conditions studied

- Advanced Biliary Tract Cancer

## Interventions

- **DRUG:** Envofolimab
- **DRUG:** Lenvatinib
- **DRUG:** Gemcitabine
- **DRUG:** Cisplatin

## Key facts

- **NCT ID:** NCT05410197
- **Lead sponsor:** Sun Yat-sen University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-10-10
- **Primary completion:** 2024-08-01
- **Final completion:** 2025-08-01
- **Target enrollment:** 43 (ESTIMATED)
- **Last updated:** 2022-10-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05410197

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05410197, "Envofolimab and Lenvatinib Combined With Gemcitabine Plus Cisplatin for Advanced BTC as First-Line Treatment(ENLIGHTEN)". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT05410197. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*